We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

53 hedge funds and large institutions have $389M invested in ArriVent BioPharma in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

68.37% more ownership

Funds ownership: 0% → 68.37% (+68%)

Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
0.76%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$79.3M
2
O
OrbiMed
New York
+$61.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$39.3M
4
OCA
Octagon Capital Advisors
New York
+$39.2M
5
SI
Sofinnova Investments
California
+$34.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
26
MYDA Advisors
New York
$536K +$605K +30,000 New
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$516K +$583K +28,900 New
UOC
28
UBS O'Connor
Illinois
$468K +$528K +26,181 New
Blackstone Inc
29
Blackstone Inc
New York
$447K +$504K +25,000 New
Walleye Capital
30
Walleye Capital
New York
$447K +$504K +25,000 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$406K +$458K +22,707 New
PD
32
Point72 (DIFC)
United Arab Emirates
$391K +$442K +21,890 New
Morgan Stanley
33
Morgan Stanley
New York
$378K +$426K +21,141 New
Barclays
34
Barclays
United Kingdom
$254K +$287K +14,208 New
N
35
Nuveen
North Carolina
$231K +$261K +12,932 New
JP Morgan Chase
36
JP Morgan Chase
New York
$224K +$253K +12,556 New
UBS Group
37
UBS Group
Switzerland
$177K +$200K +9,895 New
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$174K +$197K +9,765 New
MIM
39
MetLife Investment Management
New Jersey
$98.5K +$111K +5,514 New
AIG
40
American International Group
New York
$86.5K +$97.7K +4,845 New
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$83.2K +$94K +4,659 New
CSS
42
Cubist Systematic Strategies
Connecticut
$77.9K +$87.9K +4,360 New
Wells Fargo
43
Wells Fargo
California
$57.7K +$65.2K +3,231 New
Bank of America
44
Bank of America
North Carolina
$40.3K +$45.6K +2,259 New
Citigroup
45
Citigroup
New York
$31.1K +$35.1K +1,741 New
SO
46
STRS Ohio
Ohio
$30K +$34.3K +1,700 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$17.7K +$19.9K +989 New
AIP
48
Ameritas Investment Partners
Nebraska
$17.5K +$19.8K +981 New
Legal & General Group
49
Legal & General Group
United Kingdom
$16.1K +$18.1K +896 New
TRCT
50
Tower Research Capital (TRC)
New York
$10.8K +$12.2K +604 New
1
2
3

AVBP Hedge Fund Activity: Q1 2024 in Review

53 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2024, worth a combined $389M.

Buyers outnumbered sellers: 53 funds opened new AVBP positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was HHLR Advisors, opening a new position worth an estimated $79.3M.

  • 53 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $389M of ArriVent BioPharma stock for Q1 2024.
  • 53 funds opened new ArriVent BioPharma positions in Q1 2024 and 0 closed out, a net change of +53 holders.
  • The largest ArriVent BioPharma buyer in Q1 2024 was HHLR Advisors, an estimated $79.3M added.

Based on aggregated 13F filings for Q1 2024.